Pavilion Capital
VC Fund
New York, United States
Pavilion Capital is a VC fund in New York focused on Biotechnology and Health Care. Pavilion Capital Partners is a growth-oriented private equity investor. It provides capital and strategic support to companies in the United States and Asia. In particular, the focus is on industries experiencing high growth due to globalization, technology, or demographic trends. It actively works with company founders/management to assistin strategic initiatives, mergers and acquisitions, and eventual liquidity. The pavilion is partnered with family offices and private equity funds and is based in New York City.
- Total investments:
- 75
- Last investment:
- Lead investor:
- 19%
- Fund size:
- $50M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Pavilion Capital invests in
Stages Pavilion Capital invests in
Countries Pavilion Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
2 more contacts available
Round size
- Series A
- $2M–$67M
- Series B
- $17M–$150M
- Series C
- $35M–$200M
Investment Focus
Industry
- Biotechnology 17 (23%)
- Health Care 12 (16%)
- Information Technology 9 (12%)
- Medical 7 (9%)
- E-Commerce 7 (9%)
Stage
- Series B 19 (25%)
- Series A 15 (20%)
- Series C 12 (16%)
- Series D 7 (9%)
- Venture - Series Unknown 6 (8%)
Country
- United States 16 (21%)
- Japan 9 (12%)
- Singapore 9 (12%)
- Indonesia 8 (11%)
- South Korea 6 (8%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Timothy Low
Healthcare Investment Consultant
|
Healthcare Investment Consultant | Total investments: 4 | Find email | |
Jean-Francois Perrault
Founder
|
Founder | Total investments: 0 | Find email | |
|
Tow Heng Tan
CEO
|
CEO | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Lhoopa
|
Lhoopa is a property technology venture dedicated to revolutionizing the affordable housing sector in emerging markets. By leveraging data and innovative solutions, the company empowers local partners to provide affordable homes, addressing the significant housing backlog. | $20M / Series B / Jul 16, 2024 | |
Rebellions
|
AI chip architects are often inattentive to advanced deep learning features and requirements because they believe software stacks between their silicon and algorithms can provide effective abstract layers. We disagree. We do not think such naively designed chips can efficiently utilize expensive custom silicon resources. The more native hardwaresupports are enabled, the higher performance is achieved.Rebellions Inc is building genuine AI accelerators by bi-directionally bridging the gap between underlying silicon architectures and deep learning algorithms. We push algorithm boundaries to better exploit silicon budgets, while re-architecting AI processors to incorporate sophisticated deep learning features through silicon-dedicated DL kernels.Our goal is to deliver a domain-specific AI processor along with its optimized software. This approach, together with our unique decentralized programming model, will enable customers to arm with the most powerful yet energy-efficient AI hardware as well as seamless integration. | $123.7M / Series B / Jan 29, 2024 | |
Fleet Space Technologies
|
Fleet is an agile space company connecting the Internet of Things around the world using a massive fleet of small low-cost satellites. We’re making it faster, simpler and cheaper to connect the world’s devices.We provide direct, global access to a secure low-cost low-bandwidth connectivity platform ideal for machine to machine data exchange anddeploying IoT sensor networks at scale. With simple device setup and management through a web interface and powerful cognitive analytics built in, the IoT is about to take a giant leap forward.Our mission is to Connect Everything using cutting-edge communications and space technologies to maximize the resource efficiency of human civilization and enable the next industrial revolution with our free, ubiquitous connectivity platform. | $32.7M / Series C / May 24, 2023 | |
EcoSpirits
|
EcoSpirits is a closed-loop distribution system that develops low carbon and low waste spirits distribution technology. It eliminates packaging waste in the premium spirits supply chain. By dramatically reducing packaging and transport costs, ecoSPIRITS provides both a powerful cost advantage and a transformative carbon footprint reduction. | $10M / Series A / May 02, 2023 | |
Travelio
|
Travelio is an online short-term home rental marketplace that provides apartments, villas, and houses. Its platform allows its clients to reserve and choose houses, villas, and apartments online. Travelio was founded in March 24, 2015, by Christine Amanda, Christina Suriadjaja, and Hendry Rusli. | Series C / Apr 10, 2023 | |
Flare Therapeutics
|
Flare Therapeutics is a biotechnology company opening up a new therapeutic space with a novel approach to decipher the biology of transcription factors to develop small molecule medicines. Based on insights from the seminal work of its scientific founders, Flare’s team has uncovered ‘switch sites,’ druggable regions that are key targets fortranscription factor regulation to address mutations that cause disease. Its drug discovery to target switch sites has rapidly advanced, resulting in an emerging pipeline of drug programs that address well-validated transcription factors, initially focused on precision oncology with future potential in neurology, rare genetic disorders, immunology, and inflammation. | $123M / Series B / Mar 22, 2023 | |
Medigo Software
|
Medigo is a technology platform that connects high-quality medical services to users for providing remote medical consultations. | $2M / Series A / Mar 12, 2023 | |
JNPMEDI
|
JNPMEDI is a Clinical Trial Platforms company that offers services as a Clinical Research Organization (CRO), investment assistance, and licensing consulting. It also delivers clinical data management and operational services that adhere to international standards via its proprietary platform. The organization provides capabilities for clinicaldata management, operations, clinical trials, and quality control, all grounded in international standards through its unique platform. | $10.3M / Series A / Nov 22, 2022 | |
Vow
|
Vow is defining a new category of food using cultured meat technology. Rather than breeding and slaughtering animals, Vow is a producer of meat aimed to make their product from meat cells.The company's animal biopsies are used in a cultivator with the assistance of a nutrient-dense medium. This method allows the company to save naturalresources.Vow was established in April 2013 by George Peppou in Sydney, New South Wales. | $49.2M / Series A / Nov 14, 2022 | |
LevitasBio
|
Levitas, Inc. is redefining cellular analytics with its novel platform magnetic levitation technology. Their disruptive technology overcomes the current technological limitation of cellular analysis by providing label-free, simple, and universal methods of analysis. The company's platform, the LeviCell enables studies and beneficial uses ofpreviously inaccessible, high-value primary samples, and sensitive cell types regardless of the starting cell number, viability, or sensitivity to processing. | $35M / Series C / Oct 24, 2022 | |
| See all 75 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Pavilion Capital invest in?
Pavilion Capital invests primarily in Biotechnology, Health Care and Information Technology startups, most often at Series B and Series A stage. Most of the 75 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Pavilion Capital's check size?
Pavilion Capital typically joins rounds of $2M–$67M at Series A, $17M–$150M at Series B and $35M–$200M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Pavilion Capital participates in.
How do I contact Pavilion Capital?
Public channels for Pavilion Capital include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Pavilion Capital?
The team at Pavilion Capital includes Timothy Low (Healthcare Investment Consultant), Jean-Francois Perrault (Founder) and Tow Heng Tan (CEO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
